Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board
Industry veteran Doug Williams is back with a new approach to CAR-T cell therapies that he expects to take into the clinic in the US …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
